Join us on Wednesday, June 14^th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Astellas and Seagen Inc.

Wednesday, June 14, 2023
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

What I Tell My Patients About ...

MODULE 1: The Implications of Tumor Sidedness for Treatment Selection in Metastatic Colorectal Cancer (mCRC)

MODULE 2: The Role of BRAF-Targeted Therapy in the Treatment of mCRC

MODULE 3: Current and Future Integration of Therapies Targeting HER2 in mCRC

MODULE 4: Incidence and Management of Toxicities with Trastuzumab Deruxtecan (T-DXd)

MODULE 5: Tolerability of Tucatinib/Trastuzumab

MODULE 6: The Role of Immune Checkpoint Inhibitors in the Management of mCRC

MODULE 7: Current and Potential Role of Regorafenib and Other Kinase Inhibitors in the Treatment of Relapsed/Refractory (R/R) mCRC

MODULE 8: Adjuvant Anti-PD-1 Antibody Therapy for Esophageal Cancer

MODULE 9: First-Line Therapy for Metastatic Gastroesophageal Cancers

MODULE 10: Tolerability of Immune Checkpoint Inhibitors

MODULE 11: Targeted Therapies for HER2-Positive Gastric/Gastroesophageal Junction (GEJ) Cancer

MODULE 12: Ramucirumab in Therapy for R/R Gastric/GEJ Cancer

MODULE 13: The Role of TAS-102 in the Treatment of Advanced Gastric/GEJ Cancer and CRC

MODULE 14: Promising Investigational Strategies for Gastroesophageal Cancers

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal and gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Educate patients with metastatic colorectal cancer (mCRC) on the importance of biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment in the selection and sequencing of therapy.
• Appreciate published research documenting the efficacy of combined BRAF and EGFR inhibition for relapsed/refractory mCRC with BRAF V600E mutation, and understand how this approach is being optimally incorporated into patient care.
• Evaluate available data with and the FDA approvals of various immune checkpoint inhibitor-based approaches for microsatellite instability-high or mismatch repair-deficient mCRC, and identify patients who may benefit from this form of therapy.
• Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future role of various investigational approaches.
• Assess the relevance of HER2 status, PD-L1 combined positive score, clinical factors and personal preferences in order to develop strategies for counseling patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer about personalized treatment recommendations.
• Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric/GEJ cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
• Recall the biological rationale for and available data with HER2-targeted therapy for patients with HER2-overexpressing gastric/gastroesophageal junction cancer, and discern the current and potential clinical applicability of available treatment strategies.
• Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with colorectal and gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
• Recall available and emerging data with investigational agents and strategies currently in clinical testing for colorectal and gastroesophageal cancers, and appropriately refer eligible patients for trial participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
https://www.researchtopractice.com/Meetings/ONS2023/GI/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Wagner has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Ciombor – Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc.